Meeting
2015 ASCO Annual Meeting
Pharmacodynamic (PD) assessment using FLT-PET/CT imaging in patients treated with an interrupted high-dose axitinib schedule.
Authors
Ludimila Cavalcante
University of Wisconsin, Madison, WI
Ludimila Cavalcante , Matt Scarpelli , Lakeesha Carmichael , Jennifer Heideman , Scott Perlman , Robert Jeraj , Glenn Liu , Justine Yang Bruce
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Other
Clinical Trial Registration Number
NCT01540526
Citation
J Clin Oncol 33, 2015 (suppl; abstr 11105)
DOI
10.1200/jco.2015.33.15_suppl.11105
Abstract #
11105
Poster Bd #
319
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Safety, pharmacodynamic, and clinical response evaluation of nilotinib and paclitaxel in adults with refractory solid tumors.
First Author: Sarah Shin
Poster
2022 ASCO Annual Meeting
![[<sup>18</sup>F]Fluorothymidine(FLT)-PET imaging of thymidine kinase 1 pharmacodynamics in non-small cell lung cancer treated with pemetrexed.](https://d201v5jt9ylckg.cloudfront.net/288/14358/210839/210839_A1308_poster_pv.jpg)
[18F]Fluorothymidine(FLT)-PET imaging of thymidine kinase 1 pharmacodynamics in non-small cell lung cancer treated with pemetrexed.
First Author: Preetha Aravind
Poster
2011 ASCO Annual Meeting
![Axitinib inhibition of [<sup>18</sup>F] fluorothymidine (FLT) uptake in patients (pts) with colorectal cancer (CRC): Implications for cytotoxic chemotherapy combinations.](https://d201v5jt9ylckg.cloudfront.net/102/6667/62837/62837_poster_pv.jpg)
Axitinib inhibition of [18F] fluorothymidine (FLT) uptake in patients (pts) with colorectal cancer (CRC): Implications for cytotoxic chemotherapy combinations.
First Author: C. Hoh
Poster
2011 ASCO Annual Meeting
Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor.
First Author: S. Leijen